PGIM Short Duration High Yield ETF (PSH)
- Previous Close
50.68 - Open
50.73 - Bid 50.68 x 900
- Ask 50.73 x 800
- Day's Range
50.70 - 50.73 - 52 Week Range
49.77 - 51.09 - Volume
11,603 - Avg. Volume
4,903 - Net Assets 28M
- NAV 50.57
- PE Ratio (TTM) --
- Yield --
- YTD Daily Total Return 7.03%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.45%
The fund will seek to achieve its investment objective by investing primarily in a diversified portfolio of high yield fixed income instruments that are rated below investment grade by a NRSRO or, if unrated, are considered by the subadviser to be of comparable quality. Under normal circumstances, the fund invests at least 80% of its investable assets in high yield fixed income instruments that are rated below investment grade (commonly referred to as junk bonds) and other investments (including derivatives) with similar economic characteristics.
PGIM Investments
Fund Family
High Yield Bond
Fund Category
28M
Net Assets
2023-12-14
Inception Date
Performance Overview: PSH
View MoreTrailing returns as of 10/15/2024. Category is High Yield Bond.
People Also Watch
Holdings: PSH
View MoreSector Weightings
Recent News: PSH
View More
Research Reports: PSH
View MoreEli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
RatingPrice TargetPfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice TargetRaising target price to $36.00
HORACE MANN EDUCATORS has an Investment Rating of HOLD; a target price of $36.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRating increased to a HOLD
PROASSURANCE CORP has an Investment Rating of HOLD; a target price of $11.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target